Abstracts

464 – Distinct Signatures of Trained Immunity Reveal Heterogeneity Among Elite HIV Controllers

Background Elite Controllers (ECs) are individuals who suppress HIV replication without treatment. Understanding these mechanisms can provide insights for developing novel therapeutic strategies. By learning from their responses, we can identify key pathways and immune functions that could enhance viral control in the HIV-infected population. This study aims to investigate ECs using a multiomics approach…

457 – Investigating the Effects of ADCC and CAR NK/T Cells on HIV-1 Cell-to-Cell Transmission

Background Background Despite the success of antiretroviral therapy in controlling HIV-1 replication, achieving a cure remains a significant challenge. One obstacle to blocking HIV-1 replication is the efficient cell-to-cell transmission (C-CT) of HIV-1, which is highly resistant to broadly neutralizing antibodies (bnAbs). Here, we studied the effects of immune-based strategies, including antibody-dependent cellular cytotoxicity (ADCC)…

471 – CITE-Seq and Single Cell αβ TCRseq Unravels HIV-1 Specific GZMB Subset in Post-Treatment Controllers

Background Earlier studies have described a subset of clonally expanded, granzyme B (GZMB) Th1 memory CD4 T cells in people living with HIV. A deeper characterization of these cells in people that display ART-free virological control may contribute to our understanding of their role in anti-HIV-1 T cell responses. Methods We conducted single cell transcriptome,…

467 – Longitudinal Phenotypic and Transcriptional Profiling of Immune Cells in Early-Treated Acute HIV

Background Despite early antiretroviral treatment (ART) initiation, persistent immunological alterations have been described in individuals treated during acute HIV infection (AHI). We performed longitudinal phenotypic and transcriptional profiling of peripheral blood mononuclear cells (PBMCs) after AHI to better understand the impact of early ART on cellular immune responses.  Methods We conducted 26-color flow cytometry on…

423 – Identification of an Autoantibody Against FCHSD2 in Adipose Tissue of PLWH With Diabetes

Background Cardiovascular disease (CVD) risk is 1.5- to 2-fold higher in people living with HIV (PLWH). The heightened risk persists despite suppression of plasma viremia and control of traditional risk factors, partly due to chronic inflammation. Subcutaneous adipose tissue (SAT) regulates metabolic health, but inflammation and insulin resistance can shift its secretome to a pro-inflammatory,…

435 – An AI-Redesigned Contemporary HIV-1 Env Consensus Antigen Is More Immunogenic Than a Native Sequence

Background There is a need to design novel HIV-1 vaccine candidates that could elicit broadly neutralizing antibodies (bnAbs) and that reflect currently circulating viruses. Here we tested a subtype B envelope (Env) consensus designed in silico with shortened hypervariable loops and a native B Env to compare their Ab binding and neutralizing responses in rabbits.  Methods A…

440 – Immune Response to Mpox in PWH and PrEP Users After Infection, but Not in Response to Vaccination

Background In May 2022, WHO considered the outbreak of mpox infection as a public health emergency of international concern (PHEIC). Vaccination was recommended for people living with HIV (PWH) and users of pre-exposure prophylaxis (PrEP). The need to vaccinate the population at risk worldwide, mainly PWH and PrEP users has increased. The immune response generated…

448 – Elucidating the Role of Natural Killer Cells in Antibody Breadth During HIV Infection

Background Natural Killer (NK) cells are underappreciated regulators of the antibody response to infection. In mice, NK cells can kill T follicular helper cells which decreases somatic hypermutation and vaccine response. In the context of HIV, dysfunctional NK cells are associated with broadly neutralizing antibodies. Understanding the temporal immune factors that influence breadth is an…

419 – In Nonsuppressible Viremia, HIV Env Can Maintain Resistance to Autologous Neutralizing Antibodies

Background Nonsuppressible viremia (NSV) represent a subset of individuals with persistent low-level viremia due to a hyperactive HIV reservoir. Little is known about whether persistent antigenemia during NSV can induce a stronger immune response. Autologous neutralizing antibodies (aNAb) represent a key adaptive immune response for viral control and HIV rebound during treatment interruption has been…